Arcus Biosciences, Inc.

For the period ended Sep 30, 2025. Filed Oct 28, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 28, 2025

RCUS$18.95+3.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In millions, except per share amounts)

	September 30,2025	December 31,2024
ASSETS
Current assets:
Cash and cash equivalents	$238	$150
Marketable securities	593	828
Receivable from collaboration partners ($— and $6 from a related party)	11	20
Prepaid expenses and other current assets	15	18
Total current assets	857	1,016
Long-term marketable securities	10	14
Property and equipment, net	42	47
Other noncurrent assets	65	73
Total assets	$974	$1,150
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ($29 and $— to a related party)	$42	$18
Deferred revenue ($52 and $85 to a related party)	52	85
Other current liabilities	141	123
Total current liabilities	235	226
Deferred revenue, noncurrent ($53 and $234 to a related party)	53	234
Long-term debt	98	48
Other noncurrent liabilities	152	157
Commitments
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 107.1 shares in 2025 and 92.2 shares in 2024 issued and outstanding	1,815	1,617
Accumulated deficit	(1,379)	(1,132)
Total stockholders’ equity	436	485
Total liabilities and stockholders’ equity	$974	$1,150

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.